KWANGDONG PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
KWANGDONG PHARMACEUTICAL CO.,LTD's Market Cap is ₩3127B. At end of 2025 it was ₩2918B. Ranked #600 of 2,405 in KR market (top 25%), #356 of 778 on KOSPI (top 46%), #62 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 27%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 312.74B KRW | KR#600/2,405 Sec#62/231 |
| Revenue | 1.71T KRW | KR#286/2,405 Sec#8/231 |
| Net Income | 22.94B KRW | KR#655/2,405 Sec#42/231 |
| Total Assets | 1.32T KRW | KR#403/2,405 Sec#19/231 |
| Net Assets | 711.80B KRW | KR#384/2,405 Sec#24/231 |
| Employees | 1,072 | KR#243/2,405 Sec#15/231 |
| Value | ||
| P/E | 13.64x | KR#1,041/2,405 Sec#62/231 |
| P/B | 0.44x | KR#741/2,405 Sec#27/231 |
| P/S | 0.18x | KR#368/2,405 Sec#6/231 |
| EV/EBITDA | 14.25x | KR#872/2,405 Sec#51/231 |
| FCF Yield | 18.27% | KR#389/2,405 Sec#8/231 |
| Profitability | ||
| ROE | 3.22% | KR#1,309/2,405 Sec#91/231 |
| ROA | 1.74% | KR#1,270/2,405 Sec#91/231 |
| Op. Margin | 1.96% | KR#1,383/2,405 Sec#97/231 |
| Revenue Growth | 5.50% | KR#1,160/2,405 Sec#114/231 |
| Earnings Growth | -16.34% | KR#909/2,405 Sec#57/231 |
| Financial Health | ||
| Debt Ratio | 85.49% | KR#1,410/2,405 Sec#163/231 |
| Total Debt | 306.19B KRW | KR#402/2,405 Sec#22/231 |
| FCF | 57.15B KRW | KR#273/2,405 Sec#15/231 |
| Cash | 140.99B KRW | KR#359/2,405 Sec#15/231 |
| Current Ratio | 1.34x | KR#1,324/2,405 Sec#140/231 |
| Net Debt/EBITDA | 4.93x | KR#1,021/2,405 Sec#76/231 |
| Dividend | ||
| Div. Yield | 1.60% | KR#1,013/2,405 Sec#56/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | 9.98% | KR#444/2,405 Sec#26/231 |
| 1M Return | -4.12% | KR#627/2,405 Sec#65/231 |
| From 52W High | -50.94% | KR#1,218/2,405 Sec#97/231 |
| 1Y MDD | -52.44% | KR#1,061/2,405 Sec#86/231 |
| Trading | ||
| Volume | 73,926 shares | KR#761/2,405 Sec#79/231 |
| Trading Value | 462.1M KRW | KR#832/2,405 Sec#88/231 |
| Foreign Own. | 16.18% | KR#291/2,405 Sec#16/231 |
| Per Share | ||
| EPS | 461 KRW | KR#1,027/2,405 Sec#72/231 |
| BPS | 14,293 KRW | KR#730/2,405 Sec#49/231 |
Company Info
Kwangdong Pharmaceutical, established in 1963 and headquartered in Gwacheon-si, Gyeonggi-do, secured domestic consignment sales rights for Samdasoo until 2029 through a re-contract with Jeju Development Corporation in 2025. The company operates a Pharmacy Business Division for traditional medicines like Ssanghwatang and Woohwangchungsimwon, and an ETC Business Division for specialized pharmaceuticals such as the anti-cancer drug Lenara and vascular fortifier Venitol. Its F&B Sales Division markets beverages like Vita500, Corn Silk Tea, Hogaengnamu Tea, and Jeju Samdasoo, solidifying its brand power in the pharmaceutical and food sectors.